# Correction: Network pharmacology, bioinformatics and in vitro/in vivo validation elucidate the anti-lung cancer activities and potential targets of Rhoifolin

**Authors:** Jing Qian, Wei Cheng, Shuangyan Li, Li Deng, Di Gao, Xue Zhang, Yunhui Zhang

PMC · DOI: 10.3389/fphar.2026.1788169 · Frontiers in Pharmacology · 2026-02-12

## Full-text entities

- **Genes:** CDH2 (cadherin 2) [NCBI Gene 1000] {aka ACOGS, ADHD8, ARVD14, CD325, CDHN, CDw325}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, CDH1 (cadherin 1) [NCBI Gene 999] {aka Arc-1, BCDS1, CD324, CDHE, ECAD, LCAM}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, EPHB2 (EPH receptor B2) [NCBI Gene 2048] {aka BDPLT22, CAPB, DRT, EK5, EPHT3, ERK}
- **Diseases:** lung cancer (MESH:D008175)
- **Chemicals:** Rhoifolin (MESH:C089378), Hydrogen (MESH:D006859), N (MESH:D009584)
- **Cell lines:** H358 — Homo sapiens (Human), Minimally invasive lung adenocarcinoma, Cancer cell line (CVCL_1559), H1299 — Homo sapiens (Human), Lung large cell carcinoma, Cancer cell line (CVCL_0060)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12936559/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12936559/full.md

---
Source: https://tomesphere.com/paper/PMC12936559